Fluticasone / Salmeterol (Advair Diskus)
Pronunciation: Not established from the source reviewed for this draft..
- Generic name
- fluticasone propionate and salmeterol
- Brand names
- ADVAIR DISKUS
- Drug class
- Combination inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA)
- Form
- Dry-powder inhaler (Diskus)
- Route
- Oral inhalation
- Legal status
- Not established from the source reviewed for this draft; confirm current legal/prescription status with a pharmacist or prescriber.
Availability and supply rules vary by country
Trade names by country: United States
Australia: · Full directory
What fluticasone propionate and salmeterol is and how it works
Fluticasone/salmeterol (Advair Diskus) is a twice-daily maintenance inhaler that combines an inhaled corticosteroid (fluticasone) with a long-acting beta2-agonist (salmeterol). It is used for asthma and chronic obstructive pulmonary disease (COPD). Detailed mechanism-of-action wording (e.g., how each component acts in the airway) was not established from the source reviewed for this draft; see Professional information for the supported drug-class description only. (1)
It is not a rescue inhaler and does not relieve sudden breathing difficulty. A prescriber must confirm the diagnosis, indication, and correct strength. The exact approved uses, ages, and strengths differ by country; the information here reflects the US product label reviewed.
Mechanism of action: how fluticasone propionate and salmeterol works
Fluticasone propionate is an inhaled corticosteroid; salmeterol xinafoate is a long-acting beta2-adrenergic agonist (LABA). Detailed mechanism-of-action wording beyond drug-class identification was not established from the source reviewed for this draft. (1)
What fluticasone propionate and salmeterol is used for
Asthma maintenance
Twice-daily maintenance treatment of asthma in patients aged 4 years and older whose asthma is not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an ICS and a LABA. (1)
COPD maintenance
Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. (1)
Before taking fluticasone propionate and salmeterol
Do not take / not appropriate for
- Do not use Advair Diskus to treat sudden breathing problems or as a rescue inhaler for acute bronchospasm. (all indications) (1)
- Tell your prescriber and pharmacist about every other inhaler or medicine you use, including its active ingredients, so they can check whether it also contains a LABA — combining two LABA-containing medicines is not recommended because of the risk of LABA overdose. (all products) (1)
- Do not initiate Advair Diskus during rapidly deteriorating or potentially life-threatening asthma or COPD episodes. (all indications) (1)
Tell your clinician about
- Any heart condition, including coronary artery disease, cardiac arrhythmias, or high blood pressure.
- Any infection, including active or quiescent pulmonary tuberculosis, untreated fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex.
- Known severe milk-protein allergy (the device contains lactose, which may contain trace milk protein).
- Any history of osteoporosis or risk factors for decreased bone mineral density.
- Any eye problems, including glaucoma, increased intraocular pressure, or cataracts.
How to take fluticasone propionate and salmeterol
- Advair Diskus is inhaled by mouth twice daily, approximately 12 hours apart.
- After each inhalation, rinse the mouth with water and spit it out without swallowing, to help reduce the risk of oral thrush.
- Use exactly the strength and number of inhalations prescribed for your condition. Do not change the dose or stop treatment yourself.
- Advair Diskus is not a rescue inhaler and does not relieve sudden symptoms; ask your prescriber what to use for sudden breathing difficulty.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)
Missed dose
Specific missed-dose instructions were not identified in the source reviewed. Contact the prescribing clinic for guidance; do not take an extra dose without advice from your prescriber or pharmacist.
Overdose
A specific overdose-management protocol was not identified in the source reviewed. If overdose is suspected, seek medical attention promptly and let the treating clinician assess and advise.
Side effects
Effects vary with indication and age. The corticosteroid component can cause local mouth/throat effects; the LABA component can cause cardiovascular and central nervous system effects.
Upper respiratory tract infection, throat irritation, and hoarseness
What to notice: Sore throat, pharyngitis, voice changes, or dysphonia.
What to do: Report to the treatment team if bothersome or persistent. (1)
Oral candidiasis (thrush)
What to notice: White patches in the mouth or on the tongue, soreness, or difficulty swallowing.
What to do: Tell the treatment team; mouth rinsing after each use reduces risk. (1)
Headache and cough
What to notice: Symptom frequency and severity may depend on the treated condition.
What to do: Discuss persistent symptoms with the prescriber. (1)
Paradoxical bronchospasm
What to notice: Sudden wheezing or breathing difficulty immediately after using the inhaler.
What to do: Seek medical attention promptly and let the clinician you see decide whether this medicine should be continued. (1)
Pneumonia (in COPD patients)
What to notice: A specific symptom checklist for pneumonia was not identified in the source reviewed; any new or worsening respiratory symptoms in a COPD patient should be assessed promptly.
What to do: Contact the treatment team promptly for assessment, especially if you are over 65, have a low body mass index, or have more severe COPD — an increased risk of pneumonia has been observed in these groups. (1)
Signs of high corticosteroid levels (hypercorticism) or adrenal suppression
What to notice: A specific symptom checklist was not identified in the source reviewed; this is a known risk of inhaled corticosteroid therapy, particularly at higher-than-recommended doses or when transferring from a systemic corticosteroid.
What to do: Contact the prescriber if you have any concerns; do not alter the dose yourself. (1)
Serious warnings
Asthma-related death risk with LABA monotherapy — boxed_warning
Symptoms: This is an informational warning, not a symptom. LABAs used alone for asthma increase the risk of asthma-related death; salmeterol in this product is combined with an inhaled corticosteroid, and trials of the combination have not shown a significant increase in asthma-related deaths or hospitalizations compared with the corticosteroid alone.
Action: Use this medicine only as prescribed, and ask your prescriber or pharmacist before using any other inhaler, in case it also contains a LABA. (1)
Hypersensitivity reaction — emergency
Symptoms: Rash, hives, swelling of the face/mouth/tongue, breathing difficulty, or anaphylaxis.
Action: Seek emergency care; let the treating clinician decide whether the medicine should be continued. (1)
Acute asthma or COPD exacerbation — emergency
Symptoms: Rapidly worsening or severe shortness of breath.
Action: Seek emergency medical care. Advair Diskus is not rescue therapy and does not relieve sudden breathing difficulty. (1)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole) | Can increase fluticasone propionate levels, raising the risk of systemic corticosteroid effects including Cushing's syndrome and adrenal suppression. | Co-administration is not recommended; inform the prescriber and pharmacist of all medicines you take. (1) |
| Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants | May potentiate the cardiovascular effects of salmeterol. | Use with extreme caution or avoid; ensure the prescriber knows about all current medicines. (1) |
| Beta-adrenergic-receptor blocking agents (beta-blockers) | May block the lung effect of salmeterol and can cause severe bronchospasm in patients with reversible airway disease. | Generally avoided; if a beta-blocker is required, a cardioselective agent should be considered. Do not stop or add a beta-blocker without specialist guidance. (1) |
| Non-potassium-sparing diuretics (loop or thiazide diuretics) | Electrocardiographic changes and/or low potassium from these diuretics may worsen with salmeterol. | Use with caution; monitoring may be needed. (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Children and adolescents
Advair Diskus is approved for asthma maintenance in children aged 4 years and older. The prescriber selects the appropriate strength. Growth should be monitored regularly in pediatric patients because reduced growth velocity has been observed with long-term inhaled corticosteroid use. (1)
Pregnancy and breastfeeding
No pregnancy- or lactation-specific dosing guidance was identified in the source reviewed. Discuss benefits, risks, and disease-control needs with the prescriber. (1)
People with severe milk-protein allergy
Advair Diskus contains lactose, which may carry trace levels of milk protein. Patients with severe milk-protein allergy should be advised of this risk before use. (1)
People with cardiovascular disorders
Salmeterol can cause clinically significant changes in pulse rate, blood pressure, or symptoms. Use with caution in patients with coronary insufficiency, cardiac arrhythmias, or hypertension. (1)
Monitoring
Before starting
- Confirm the diagnosis, indication, and that the patient is not in a rapidly deteriorating or life-threatening episode.
- Assess cardiovascular status, including coronary artery disease, arrhythmias, and hypertension.
- Screen for infections including active or quiescent tuberculosis, untreated fungal/bacterial/viral/parasitic infections, and ocular herpes simplex.
- Evaluate bone-mineral-density risk factors and ocular history (glaucoma, cataracts).
- Ask about severe milk-protein allergy, and all current medicines especially other LABAs, strong CYP3A4 inhibitors, MAOIs, tricyclic antidepressants, beta-blockers, and non-potassium-sparing diuretics.
During treatment
- Watch for signs of oral candidiasis, hoarseness, pneumonia (especially in COPD patients), paradoxical bronchospasm, hypersensitivity, hypercorticism, and adrenal suppression.
- Monitor growth in pediatric patients regularly.
- Consider ophthalmological referral for patients who develop ocular symptoms or use the product long term.
- Consider bone-mineral-density monitoring in patients with major risk factors.
- If transferring from a systemic corticosteroid, taper the systemic corticosteroid slowly to avoid adrenal insufficiency.
Storage
Specific storage-condition details (temperature/humidity) were not identified in the source reviewed. Follow the instructions on the product packaging and the patient information leaflet supplied with the device.
Professional information
Clinician-facing context only. Use the current local indication, dosing table, and formulation instructions. Only the US label was reviewed for this draft; non-US labels must be consulted for local use.
United States
Indication: Asthma maintenance (age 12 and older)
Dose summary: One inhalation of Advair Diskus 100/50, 250/50, or 500/50 twice daily, approximately 12 hours apart, with strength based on disease severity.
Renal context: No renal-dose adjustment was identified in the source reviewed. (1)
United States
Indication: Asthma maintenance (ages 4–11)
Dose summary: Strength and eligibility determined by the prescriber according to the US label; the source reviewed refers to use from age 4 years. Specific dosing-table details for ages 4–11 were not fully extracted in this pass.
Renal context: No renal-dose adjustment was identified in the source reviewed. (1)
United States
Indication: COPD maintenance
Dose summary: One inhalation of Advair Diskus 250/50 twice daily.
Renal context: No renal-dose adjustment was identified in the source reviewed. (1)
Hepatic guidance
Strong CYP3A4 inhibitors can increase fluticasone exposure; co-administration is not recommended. No specific hepatic-impairment dose adjustment was identified in the source reviewed.
Overdose note
No product-specific overdose-management protocol was identified in the source reviewed. Clinician assessment is required for any suspected overdose. (1)
Frequently asked questions
Can Advair Diskus be used as a rescue inhaler during an asthma attack?
No. Advair Diskus is a twice-daily maintenance inhaler only. You must use a separate quick-relief inhaler for sudden symptoms, as directed by your prescriber. (1)
Why do I need to rinse my mouth after using Advair Diskus?
Rinsing your mouth with water and spitting it out after each inhalation helps reduce the risk of developing oral thrush (a fungal infection in the mouth). (1)
Is the LABA in Advair Diskus dangerous?
When used alone (as monotherapy), LABAs increase the risk of asthma-related death. Advair Diskus combines the LABA with an inhaled corticosteroid, and this combination has not shown a significant increase in asthma-related deaths or hospitalizations in clinical trials compared with the corticosteroid alone. (1)
What is the mechanism of action of fluticasone propionate and salmeterol?
Fluticasone propionate is an inhaled corticosteroid; salmeterol xinafoate is a long-acting beta2-adrenergic agonist (LABA). Detailed mechanism-of-action wording beyond drug-class identification was not established from the source reviewed for this draft. (1)
What is the generic name of Fluticasone / Salmeterol (Advair Diskus)?
The generic name is fluticasone propionate and salmeterol. It is sold under brand names including ADVAIR DISKUS. (1)
What class of drug is fluticasone propionate and salmeterol?
Fluticasone / Salmeterol (Advair Diskus) is classed as: Combination inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA). (1)
References
- ADVAIR DISKUS (fluticasone propionate and salmeterol powder) — patient package insertU.S. Food and Drug Administration (DailyMed) · United States · accessed 2026-08-05 · source 1
- FLUTICASONE PROPIONATE AND SALMETEROL POWDER [CIPLA USA INC.] — US prescribing information (DailyMed SPL)U.S. National Library of Medicine (DailyMed) · US · accessed 2026-08-14 · source 2
- Fluticasone and Salmeterol Oral Inhalation — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 3
- Fluticasone Propionate and Salmeterol — FDA approval record (Drugs@FDA NDA208799)U.S. Food and Drug Administration · US · accessed 2026-08-14 · source 4
- fluticasone propionate and salmeterol — RxNorm normalized drug concept (RXCUI 284635)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 5
Brand names by country
Single-ingredient fluticasone propionate and salmeterol names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- ADVAIR HFA
- Wixela Inhub
- AirDuo RespiClick